Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Connect Biopharma Holdings Limited - Ordinary Shares
(NQ:
CNTB
)
3.240
+0.110 (+3.51%)
Streaming Delayed Price
Updated: 12:48 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Connect Biopharma Holdings Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
May 20, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
May 14, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
May 13, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
April 24, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Tuesday's after hours session: top gainers and losers
↗
April 15, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
April 11, 2025
Via
ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
April 07, 2025
Via
Benzinga
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
April 01, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
March 31, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
March 31, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
March 28, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present at Two Upcoming Investor Conferences
March 03, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
David Szekeres, President of Connect Biopharma Holdings Limited (NASDAQ: CNTB), to Present at NobleCon20
November 05, 2024
Via
Investor Brand Network
Attovia Therapeutics Appoints Chief Financial Officer
October 15, 2024
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer
From
Attovia Therapeutics, Inc.
Via
GlobeNewswire
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
September 10, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal
↗
September 07, 2024
EpimAb Biotherapeutics sold global rights for a clinical-stage asset to Vignette Bio, a San Francisco startup, in a $635 million deal. Meanwhile, Shenzhen TargetRx raised $20 million by selling China...
Via
Talk Markets
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
September 05, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
July 01, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 13, 2024
Via
Benzinga
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
June 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
May 22, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
May 07, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
April 16, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
April 03, 2024
Via
Benzinga
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
March 19, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 20, 2024
Via
Benzinga
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
February 12, 2024
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
February 02, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
